Abnormal Cortical Peritubular Capillary Morphology C5558250
A structural abnormality of small blood vessels surrounding kidney tubules. May impact kidney function and filtration. Treatment focuses on managing underlying kidney conditions.
Key facts at a glance
- ICD-10
- N28.9
- ICD-11
- GA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Shortness of breath
Difficulty breathing or feeling breathless, often due to fluid buildup in the lungs.
Immediately if experiencing severe difficulty breathing, chest pain, or bluish lips/fingertips.
Decreased urine output
(renal)Reduced amount of urine produced by the kidneys, often appearing darker or foamy.
Frequency: 70-80% of patients
Fatigue and weakness
(constitutional)Persistent tiredness, lack of energy, and general weakness that interferes with daily activities.
Frequency: 75-85% of patients
Hypertension
(cardiovascular)Elevated blood pressure due to fluid retention and impaired kidney function.
Frequency: 60-70% of patients
Peripheral edema
(renal)Swelling in the legs, ankles, feet, or around the eyes due to fluid retention.
Frequency: 50-60% of patients
Nausea and loss of appetite
(gastrointestinal)Feeling sick to the stomach and reduced desire to eat, often due to toxin buildup.
Frequency: 40-50% of patients
Flank or back pain
(renal)Dull or sharp pain in the side or lower back near the kidneys.
Frequency: 20-30% of patients
Pruritus
(dermatologic)Itchy skin, often worse at night, caused by buildup of waste products in the blood.
Frequency: 30-40% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
Renal perfusion assessment
Comprehensive monitoring of kidney perfusion and function through imaging and laboratory studies to detect functional deterioration from capillary morphology changes.
Microvascular protection therapy
Pharmacological agents aimed at protecting and potentially improving microvascular function in the renal cortex, including agents that support endothelial health.
Additional treatment options
Antioxidant-rich renal diet
Nutritional approach emphasizing foods rich in antioxidants and anti-inflammatory compounds to support capillary health and reduce oxidative stress on renal vasculature.
dietaryCardiovascular conditioning
Regular aerobic exercise to maintain cardiovascular health and optimize renal perfusion through improved cardiac output and vascular function.
lifestyleVascular intervention evaluation
Surgical consultation for consideration of revascularization or interventional procedures when significant perfusion compromise is identified.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Cortical Peritubular Capillary Morphology C5558250?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements. 2012;2(1):1-138.
Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Journal of the American Society of Nephrology. 2006;17(1):17-25.
Kida Y, Tchao BN, Yamaguchi I, et al. Peritubular capillary rarefaction: a new therapeutic target in diabetic kidney disease. Kidney Research and Clinical Practice. 2020;39(4):394-405.
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine. 2001;345(12):861-869.
KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2020;98(4):S1-S115.
Ettenson DS, Botnick B, Barraza M, Behzadian MA. The renal microcirculation in diabetes: a new therapeutic target for diabetic nephropathy. Current Opinion in Nephrology and Hypertension. 2020;29(2):167-174.
Heinz J, Kriz W. Renal microvasculature. In: Brenner and Rector's The Kidney. 11th ed. Elsevier; 2019:145-187.
Zhong Y, Garcia MK, Zhang D, et al. Association between peritubular capillary rarefaction and renal outcomes: a systematic review and meta-analysis. Scientific Reports. 2021;11(1):14456.
Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. Journal of the American Society of Nephrology. 2010;21(4):556-563.
International Society of Nephrology. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International. 2021;100(4):S1-S276.
Medication Comparisons
Compare medications used to treat Abnormal Cortical Peritubular Capillary Morphology C5558250. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy